Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 3 1

Status

Recruiting 6Terminated 5Completed 5Unknown 3Withdrawn 2Not yet recruiting 1Active not recruiting 1

Sponsor Class

OTHER 3

Study Type

Interventional 3

Sponsor

Cancer Type

Thoracic 3Dermatologic 1CNS 1Breast 1

Conditions

Multiple Myeloma 64Precursor Cell Lymphoblastic Leukemia-Lymphoma 20Neoplasms, Plasma Cell 14Recurrence 12Leukemia 12Vomiting 11Lymphoma, Extranodal NK-T-Cell 11Lymphoma 11Neoplasms 9Nausea 6Lymphoma, Mantle-Cell 6Lymphoma, Large B-Cell, Diffuse 5Lymphoma, Non-Hodgkin 4Lymphoma, Follicular 4Paraproteinemias 3Lymphoma, T-Cell, Peripheral 3Lymphoma, B-Cell, Marginal Zone 3Lymphohistiocytosis, Hemophagocytic 3Lung Neoplasms 3Immunoglobulin Light-chain Amyloidosis 3Hematologic Diseases 3Colorectal Neoplasms 3Carcinoma, Hepatocellular 3Burkitt Lymphoma 3Breast Neoplasms 3Blood Protein Disorders 3Renal Insufficiency 2Postoperative Nausea and Vomiting 2Polycystic Ovary Syndrome 2Peripheral Nervous System Diseases 2

Interventions

Cisplatin 38Carboplatin 28Gemcitabine 23Docetaxel 20Radiotherapy 18Etoposide 15Paclitaxel 13Erlotinib Hydrochloride 13Vinorelbine 11Drug Therapy 11pembrolizumab 9aumolertinib 9apatinib 9Pemetrexed 9Gefitinib 9osimertinib 7endostar protein 7Thoracic Surgery, Video-Assisted 7Blood Specimen Collection 7camrelizumab 6anlotinib 6Vinblastine 6Surgical Procedures, Operative 6sintilimab 5Radiosurgery 5Fluorodeoxyglucose F18 5Cyclophosphamide 5Bevacizumab 5durvalumab 4Mitomycin 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Unknown × Lung Neoplasms × Dexamethasone × Clear all
NCT04201769 2020-04-03

LUNG-NEPA

Consorzio Oncotech

Phase 3 Unknown
261 enrolled
Thoracic

Lung Neoplasms, Nausea, Vomiting

NCT04001725 2019-11-13

OPTIMAL

Fondazione IRCCS Istituto Nazionale dei Tumori, Milano

Phase 2 Unknown
110 enrolled
BreastCNSDermatologicThoracic

Brain Neoplasms, Breast Neoplasms, Diabetes Mellitus, Lung Neoplasms, Melanoma, Neoplasms

NCT02445872 2015-12-09

Safety and Efficacy of Aprepitant for CINV in Patients With Lung Cancer Receiving Multiple-day Cisplatin Chemotherapy

Zhejiang University

Phase 2 Unknown
80 enrolled
Thoracic

Lung Neoplasms, Nausea, Vomiting

Data powered by HemOnc (CC BY 4.0) Colophon âš¡